Human Fc gamma RIIA / CD32a (H167) Protein, His Tag (SPR & BLI verified)

Source : 

Human CD32a (H167), His Tag (SPR & BLI verified) (CD1-H5223) is expressed from human 293 cells (HEK293). It contains AA Ala 36 - Ile 218 (Accession # P12318-1).

 

Molecule : Fc gamma RIIA / CD32a

 

Synonyms : CD32a,FCGR2A,CD32,FCG2 ,FCGR2A1,IGFR2

 

Format : Powder

 

Category : MABSol® Fc Receptors

 

Accession : AAH19931.1

 

Storage : -20℃

 

Shipping condition : Powder,RT

 

Molecular Weight : 21.5 kDa

 

Characteristics :

This protein carries a polyhistidine tag at the C-terminus. The protein has a calculated MW of 21.5 kDa. The protein migrates as 29-32 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

 

Endotoxin Level : Less than 1.0 EU per μg by the LAL method.

 

Buffer : PBS, pH7.4

 

Description :

Receptors for the Fc region of IgG (Fc γ R) are members of the Ig superfamily that function in the activation or inhibition of immune responses. Three classes of human Fc γ Rs: RI (CD64), RII (CD32), and RIII (CD16), which generate multiple isoforms, are recognized.
There are three genes for human Fcγ RII /CD32 (A, B, and C) and one for mouse Fcγ RII B (CD32B). CD32 is a low affinity receptor for IgG. The activating isoform, CD32A, is expressed on monocytes, neutrophils, platelets and dendritic cells. CD32A is expressed on many immune cell types (macrophage, neutrophil, eosinophils, platelets, dendritic cells and Langerhan cells), where inhibitory ITIM­bearing receptors may also be coexpressed and co­engaged by specific ligands. CD32A delivers an activating signal upon ligand binding, and results in the initiation of inflammatory responses including cytolysis, phagocytosis, degranulation and cytokine production. The responses can be modulated by signals from the coexpressed inhibitory receptors such as CD32B, and the strength of the signal is dependent on the ratio of expression of the activating and inhibitory receptors.

 

References :

(1) Ravetch JV. et al., 2001, Annu Rev Immunol. 19: 275-83.
(2) Takai T. 2002, Nature Rev Immunol. 2: 580-92.
(3) Nagarajan S. et al., 2000, Blood. 3: 1069-77.